These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24112999)

  • 21. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder.
    Amsterdam JD; Williams D; Michelson D; Adler LA; Dunner DL; Nierenberg AA; Reimherr FW; Schatzberg AF
    Neuropsychobiology; 2009; 59(4):227-33. PubMed ID: 19571597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine-induced changes in neural network patterns supporting aversive conditioning.
    Diaconescu AO; Menon M; Jensen J; Kapur S; McIntosh AR
    Brain Res; 2010 Feb; 1313():143-61. PubMed ID: 19961836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
    Başterzi AD; Yazici K; Buturak V; Cimen B; Yazici A; Eskandari G; Tot Acar S; Taşdelen B
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):70-5. PubMed ID: 19804808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
    Hunter AM; Ravikumar S; Cook IA; Leuchter AF
    Acta Psychiatr Scand; 2009 Apr; 119(4):266-73. PubMed ID: 19077131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mechanisms of tolerance in antidepressant action.
    Fava GA; Offidani E
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1593-602. PubMed ID: 20728491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
    J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic therapy with lithium in elderly patients with unipolar major depression.
    Wilkinson D; Holmes C; Woolford J; Stammers S; North J
    Int J Geriatr Psychiatry; 2002 Jul; 17(7):619-22. PubMed ID: 12112158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of placebo rates in major depressive disorder trials.
    Stolk P; Ten Berg MJ; Hemels ME; Einarson TR
    Ann Pharmacother; 2003 Dec; 37(12):1891-9. PubMed ID: 14632596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Boulton DW; Balch AH; Royzman K; Patel CG; Berman RM; Mallikaarjun S; Reeves RA
    J Psychopharmacol; 2010 Apr; 24(4):537-46. PubMed ID: 18832427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.
    Learned S; Graff O; Roychowdhury S; Moate R; Krishnan KR; Archer G; Modell JG; Alexander R; Zamuner S; Lavergne A; Evoniuk G; Ratti E
    J Psychopharmacol; 2012 May; 26(5):653-62. PubMed ID: 22048884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurophysiologic changes during estrogen augmentation in perimenopausal depression.
    Morgan ML; Cook IA; Rapkin AJ; Leuchter AF
    Maturitas; 2007 Jan; 56(1):54-60. PubMed ID: 16835012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.